A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs NTB 011 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors NantBioScience
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.
- 23 May 2017 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
- 23 May 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.